China Hosts Five Clinical Trials for COVID-19 Vaccines
China Hosts Five Clinical Trials for COVID-19 Vaccines
BEIJING--June 4, 2021--Researched by Industrial Info Resources (Sugar Land, Texas)--Chinese pharmaceutical company Walvax Biotechnology Company Limited recently was approved to perform clinical trials for its recombinant coronavirus vaccine, according to Chinese National Medical Products Administration. To date, 640 million Chinese citizens have received a vaccine for COVID-19.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Suffolk Construction Has Hand in $1.9 Billion Worth of Projects
- U.S. Home to Billions' Worth of 2Q ESG Project Kickoffs
- Japan Hosts $832 Million in CDMO/CMO-Related Pharma Projects
- Turner Construction Involved in More than $24 Billion Worth of U.S. Project...
- Medical Devices & Equipment Sector Brings Billions in Spending to the U.S.
Quick Links
- Home
- About Us
- Contact Us
- For Traders
Global Market Intelligence
- GMI Database Platform
- GMI Platform Tools
- Industry Coverage
- Analytics & Insights
- Advertising
